> ## Content Index
> Fetch the complete content index at: https://www.healthdatacon.io/llms.txt
> Use this file to discover other available public pages before exploring further.

# Aetna wants to see how care changes before it funds a value-based partner
- URL: https://www.healthdatacon.io/articles/hlth-aetna-value-based-care-clinical-evidence/
- Published: 2026-11-16T21:50:00.000Z
- Updated: 2026-11-17T07:31:32.000Z
- Description: Aetna, Astrana Health and Alignment described what payers and providers need to see in the work behind savings.
- Author: HDM Staff
- Tags: Operations, Americas, HLTH

LAS VEGAS — When a cardiology group told Aetna it could help manage the insurer’s highest-risk patients, Chief Medical Officer Ben Kornitzer asked to put an Aetna medical director with the team for a few days. He wanted to see how the group worked and how often patients received guideline-directed treatment. The request was an example of the evidence the insurer wants before it commits to a partner that says it can improve outcomes and lower costs.

Kornitzer described the request during a [Velocity Stage panel](https://hlth.com/events/usa/agenda/2026/can-vbc-survive-2027?ref=healthdatacon.io) on the future of value-based care at HLTH USA. Baird senior equity research analyst Michael Ha moderated the discussion with Kornitzer, Astrana Health President and CEO Brandon Sim and Alignment Health Plan CEO Dawn Maroney. Ha began with a scenario that exposed a problem for these contracts: preventing a hospital admission can help a patient and lower medical spending while affecting a hospital’s revenue.

## A clinical explanation for the savings

Kornitzer said he looks for a “clinical fingerprint” in a proposed care model. He used the term to describe what an insurer can observe in the work itself, including whether a team screens people for relevant conditions and puts appropriate patients on medicines that reduce risk. In the cardiology example, the review would examine how care is delivered as well as the economic results the group says it can produce.

He also called for “common metrics” across partners. A payer with many contracts can have difficulty comparing them if each defines success differently or relies on different inputs. Kornitzer said the insurer should have confidence in what a program does clinically, even when its economic results make the arrangement attractive.

That makes the definition of a successful outcome important when a plan evaluates avoided admissions or lower spending. The cost of running the intervention and the mix of patients it serves can affect the comparison, both points Ha raised in his questioning. Observation of the workflow can help explain why results might change, although the panel did not present a controlled comparison of Aetna’s approach or give an outcome for the cardiology group.

The argument also applies when the work involves specialists. A payer can measure whether a specialist visit took place, while a clinician can ask if treatment actually changed or whether a patient was able to follow the plan. The answers may describe different parts of the same program. What Aetna asks to see in the workflow is the link between the activity being paid for and the outcomes the contract is supposed to improve.

## Paying for what happens between billable visits

Sim said some of the work a provider needs to do takes place “between visits” and is hard to bill for separately. Astrana’s approach, as he described it, is to take responsibility for total cost and quality so that the organization can help physicians do the work that does not come with an individual fee. He gave the example of helping a patient get to the site of care the primary care physician intended.

Sim used an “Iron Man suit” analogy for the support a physician can receive from the organization. He said the aim was to make physicians more effective in the care they already deliver and preserve their relationships with patients. The example shifted attention from a broad promise of more efficient care to specific work, such as getting the patient to a destination after a clinician has made a decision.

Maroney described Alignment’s Care Anywhere program, which she said serves people who are homebound or face barriers to making a conventional office visit. She said it can take “explaining the economics to all parties” to work with a hospital on a program meant to reduce avoidable use. A payer can benefit from lower spending, but a hospital still has to understand what the change means for how it uses staff and capacity.

That explanation also extends to community physicians. Maroney said Alignment has to find “coordination type incentives” that encourage physicians to work with Care Anywhere. Her account highlighted that a patient’s access to a home-based service and a physician’s willingness to use it are two separate implementation questions. The panel did not report comparable costs or rates of admission across the programs that panelists described.

## Scale depends on what reaches the local clinician

Ha used Kaiser Permanente as a point of comparison and asked whether an operator could build similar alignment without owning hospitals or employing the entire clinical workforce. Sim pointed to Kaiser’s ability to see information over the course of a patient’s care and deliver multiple services in one system. He also questioned how easily that model can be reproduced across different regions.

Kornitzer described a different possibility: national infrastructure that lets a plan partner closely with local providers. He said clinicians should be able to see relevant diagnoses, medications and encounters while they are making a decision. The design depends on how the information fits into their existing workflow and how much of a patient’s care took place outside the practice’s own systems.

One federal model illustrates why the durability of a contract matters. The CMS Innovation Center says its [LEAD model](https://www.cms.gov/priorities/innovation/innovation-models/lead?ref=healthdatacon.io) is set to follow ACO REACH after the end of 2026 and is designed around a ten-year performance period. The demonstration is distinct from the arrangements the executives were discussing. Its timeframe gives providers a separate example of how a payer can define a period over which it expects an organization to invest and improve.

Sim also discussed growing accountable care in traditional Medicare through the way beneficiaries are assigned to organizations. He framed that as a policy option and said patients should be able to retain their relationships with providers. It was a proposal made during the session, separate from CMS’s existing model design, and points to how a contract can assign financial responsibility while clinicians work across otherwise independent practices.

The discussion returned repeatedly to how a payer or provider can see the care behind the financial result. A decline in admissions may be meaningful to a plan, a hospital and a patient for different reasons. The work of sustaining it rests with teams that can explain what changed in care, who made it happen and how the contract will support that work the next time a patient needs it.